What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres

Diabetes Research and Clinical Practice

Volumn 108, Issue 3, 2015, Pages 405-413

  Fulcher, Gregory ^a   Roberts, Anthony ^b   Sinha, Ashim ^c   Proietto, Joseph ^d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b South Australian Endocrine Clinical Research   (Australia)

^c CAIRNS BASE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Drug utilisation; Glycaemic control; Incretin therapy; Insulin therapy; Medicines management

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; PREMIXED INSULIN; SHORT ACTING INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; BODY MASS; COMORBIDITY; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG THERAPY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT INTENSIFICATION; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; MEDICAL AUDIT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE;

AGED; AUSTRALIA; BLOOD GLUCOSE; CLINICAL AUDIT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84930180520     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.03.004     Document Type: Article

References (29)

1. Australian Diabetes Council. Diabetes facts - 2013 2013, Australian Diabetes Council, Available at: http://www.australiandiabetescouncil.com/ADCCorporateSite/files/b5/b51a4e10-c6c5-4082-9d48-2be56b3b81ed.pdf [accessed 10.02.14].
2. van Dieren S., Beulens J.W., van der Schouw Y.T., Grobbee D.E., Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010, 17(Suppl. 1):S3-S8.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
4. MacIsaac R., Cheung A., Jerums G. Type 2 diabetes - controlling hyperglycaemia with early insulin use. Aust Fam Physician 2010, 39(8):565-569.
5. Calvert M.J., McManus R.J., Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007, 57(539):455-460.
6. Harris S.B., Kapor J., Lank C.N., Willan A.R., Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010, 56(12):e418-e424.
7. Khunti K., Wolden M.L., Thorsted B.L., Andersen M., Davies M.J. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013, 36(11):3411-3417.
8. Peyrot M., Rubin R.R., Lauritzen T., Skovlund S.E., Snoek F.J., Matthews D.R., et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 2005, 28(11):2673-2679.
9. Shah B.R., Hux J.E., Laupacis A., Zinman B., van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?. Diabetes Care 2005, 28(3):600-606.
10. Patrick A.R., Fischer M.A., Choudhry N.K., Shrank W.H., Seeger J.D., Liu J., et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med 2014, 29(2):320-327.
11. Cohen N.D., Audehm R., Pretorius E., Kaye J., Chapman L.H., Colagiuri S. The rationale for combining GLP-1 receptor agonists with basal insulin. Med J Aust 2013, 199(4):246-249.
12. Best J.D., Drury P.L., Davis T.M., Taskinen M.R., Kesaniemi Y.A., Scott R., et al. Glycemic control over 5 years in 4900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care 2012, 35(5):1165-1170.
13. Davis T.M., Davis Cyllene Uwa Edu Au W.A., Bruce D.G. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Med J Aust 2006, 184(7):325-328.
14. Macisaac R.J., Jerums G., Weekes A.J., Thomas M.C. Patterns of glycaemic control in Australian primary care (NEFRON 8). Intern Med J 2009, 39(8):512-518.
15. Nichols G.A., Koo Y.H., Shah S.N. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007, 22(4):453-458.
16. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Am J Ophthalmol 2000, 129(5):704-705.
17. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
18. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
19. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986. The Diabetes Control and Complications Trial Research Group.
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
22. Owens D.R. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther 2013, 15(9):776-785.
23. Origin Trial Investigators Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care 2013, 36(10):2915-2922.
24. Aschner P.J., Ruiz A.J. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther 2012, 14(Suppl. 1):S68-S74.
25. Davis K.L., Tangirala M., Meyers J.L., Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin 2013, 29(9):1083-1091.
26. Levin P., Wei W., Miao R., Ye F., Xie L., Baser O., Gill J. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab 2015, 17(3):245-253.
27. Daousi C., Casson I.F., Gill G.V., MacFarlane I.A., Wilding J.P., Pinkney J.H. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006, 82(966):280-284.
28. Vilsboll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
29. Riddle M.C., Aronson R., Home P., Marre M., Niemoeller E., Miossec P., et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013, 36(9):2489-2496.